SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-180763
Filing Date
2022-06-24
Accepted
2022-06-24 07:46:02
Documents
15
Period of Report
2022-06-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d373055d8k.htm   iXBRL 8-K 25604
2 EX-99.1 d373055dex991.htm EX-99.1 40346
6 GRAPHIC g373055dsp05a.jpg GRAPHIC 13493
7 GRAPHIC g373055dsp5.jpg GRAPHIC 2135
  Complete submission text file 0001193125-22-180763.txt   221611

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ntla-20220624.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20220624_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20220624_pre.xml EX-101.PRE 11260
9 EXTRACTED XBRL INSTANCE DOCUMENT d373055d8k_htm.xml XML 3344
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 221036971
SIC: 2835 In Vitro & In Vivo Diagnostic Substances